Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma

International Journal of Oncology

Volumn 38, Issue 5, 2011, Pages 1329-1341

  Koto, Karen S ^a   Lescault, Pamela ^b   Brard, Laurent ^c   Kim, Kyukwang ^c   Singh, Rakesh K ^c   Bond, Jeff ^b   Illenye, Sharon ^b   Slavik, Marni A ^b   Ashikaga, Takamaru ^a   Saulnier Sholler, Giselle L ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Apoptosis; Medulloblastoma; Nifurtimox; Reactive oxygen species; Tetrathiomolybdate

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; CASPASE 3; DNA DAMAGE INDUCIBLE TRANSCRIPT 4; DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 1; DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 4; DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 9; DUAL SPECIFICITY PHOSPHATASE 6; GLUTAMATE CYSTEINE LIGASE; GLUTAMATE CYSTEINE LIGASE MODIFIER SUBUNIT; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45B; HEME OXYGENASE 1; HISTONE CLUSTER 1, H1B; HISTONE CLUSTER 1, H2BF; HISTONE CLUSTER 1, H2BL; HISTONE CLUSTER 1, H2BM; HISTONE CLUSTER 2, H2BE; HISTONE CLUSTER 3, H2BB; HOMOCYSTEINE ER STRESS INDUCIBLE, UBIQUITIN LIKE DOMAIN MEMBER 1; NIFURTIMOX; NUCLEAR RECEPTOR RELATED FACTOR 1; OLIGONUCLEOTIDE OLIGOSACCHARIDE BINDING FOLD CONTAINING 2A; PROTEIN; REACTIVE OXYGEN METABOLITE; SOLUTE CARRIER FAMILY 7, MEMBER 11; SULFIREDOXIN 1; TETRATHIOMOLYBDIC ACID; THIOREDOXIN INTERACTING PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; EXON; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; NUCLEOSOME; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FOLDING; RNA HYBRIDIZATION; RNA ISOLATION; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; DNA DAMAGE; DRUG SYNERGISM; HUMANS; MEDULLOBLASTOMA; MOLYBDENUM; NF-E2-RELATED FACTOR 2; NIFURTIMOX; REACTIVE OXYGEN SPECIES;

EID: 79955021821     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.971     Document Type: Article

References (76)

1. CBTRUS Supplement Report: Primary Brain Tumors in the United States. Central Brain Tumor Registry of the United States, Hindsdale, IL, 2004.
2. McNeil DE, Cote TR, Clegg L and Rorke LB: Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol 39: 190-194, 2002. (Pubitemid 34827569)
3. Grill J and Bhangoo R: Recent developments in chemotherapy of paediatric brain tumors. Curr Opin Oncol 19: 612-615, 2007. (Pubitemid 47508870)
4. Mulhern RK, Palmer SL, Merchant TE, et al: Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 23: 5511-5519, 2005.
5. Ribi K, Relly C, Landolt MA, Alber FD, Boltshauser E and Grotzer MA: Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics 36: 357-365, 2005. (Pubitemid 43162346)
6. Pan JS, Hong MZ and Ren JL: Reactive oxygen species: a double-edged sword in oncogenesis. World J Gastroenterol 15: 1702-1707, 2009.
7. Kaspar JW, Niture SK and Jaiswal AK: Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 47: 1304-1309, 2009.
8. Circu ML and Aw TY: Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48: 749-762, 2010.
9. Fang J, Seki T and Maeda H: Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Advanced Drug Deliv Rev 61: 290-302, 2009.
10. Mates JM, Segura JA, Alonso FJ and Marquez J: Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol 82: 273-299, 2008.
11. Lau AT, Wang Y and Chiu JF: Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem 104: 657-667, 2008. (Pubitemid 351671652)
12. Raether W and Hanel H: Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 90: 19-39, 2003.
13. Maya JD, Bollo S, Nunez-Vergara LJ, Squella JA, Repetto Y, Morello A, Perie J and Chauviere G: Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem Pharmacol 65: 999-1006, 2003. (Pubitemid 36293683)
14. Ramakrishna Rao DN and Mason RP: Generation of nitro radical anions of some 5-nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin. J Biol Chem 262: 11731-11736, 1987.
15. Saulnier Sholler GL, Kalkunte S, Greenlaw C, McCarten K and Forman E: Antitumor activity of nifurtimox observed in a patient with neuroblastoma. J Pediatr Hematol Oncol 28: 693-695, 2006. (Pubitemid 44536052)
16. Saulnier Sholler GL, Brard L, Straub JA, Dorf L, Illenye S, Koto K, Kalkunte S, Bosenberg M, Ashikaga T and Nishi R: Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. J Pediatr Hematol Oncol 31: 187-193, 2009.
17. Paulos C, Paredes J, Vasquez I, Thambo S, Arancibia A and Gonzalez-Martin G: Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 27: 454-457, 1989. (Pubitemid 19225360)
18. Prathalingham SR, Wilkinson SR, Horn D and Kelly JM: Deletion of the trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole. Antimicrob Agents Chemother 51: 755-758, 2007. (Pubitemid 46185302)
19. Fridovich I: Superoxide radical and superoxide dismutases. Annu Rev Biochem 64: 97-112, 1995.
20. Imlay JA and Fridovich I: Assay of metabolic superoxide production in Escherichia coli. J Biol Chem 266: 6957-6965, 1991. (Pubitemid 21906318)
21. Fridovich I: The biology of oxygen radicals. Science 201: 875-880, 1978.
22. Chidambaram MV, Barnes G and Frieden E: Inhibition of ceruloplasmin and other copper oxidases by thiomolybdate. J Inorg Biochem 22: 231-239, 1984. (Pubitemid 15155852)
23. Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ and Lorincz MT: Treatment of Wilson's disease with tetrathiomolybdate: V. control of free copper by tetrathiomolybdate and a comparison with trientine. Translational Res 154: 70-77, 2008.
24. Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF, Merajver SD and Zalupski MM: A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-fluoracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs 27: 159-165, 2009.
25. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ and Merajver SD: Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9: 1666-1672, 2003. (Pubitemid 36554589)
26. Brewer GJ, Dick RD, Grover DK, et al: Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 6: 1-10, 2006.
27. Lowndes SA, Adams A, Timms A, et al: Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res 14: 7526-7534, 2008.
28. Pass HI, Brewer GJ, Dick R, Carbone M and Merajver S: A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 86: 383-390, 2008. (Pubitemid 351978017)
29. Kurisaka M and Mori K: Immunohistochemical study of medulloblastoma with a monoclonal antibody against human copper and zinc-superoxide dismutase. Neurol Med Chir 36: 220-223, 1996. (Pubitemid 26138035)
30. Hileman EO, Liu J, Albitar M, Keating MJ and Huang P: Instrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 53: 209-219, 2004. (Pubitemid 38293718)
31. Dincer Z: Copper toxicity in sheep: studies on copper chelation by ammonium tetrathiomolybdate (TTM) and metallothionein. [dissertation]. University of Liverpool, Liverpool, 1994.
32. R Development Core Team. R: A Language and Environment for Statistical Computing. Available from: http://www.R-project.org, 2009.
33. Gentleman RC: Bioinformatics and computational biology solutions using R and Bioconductor, in statistics for biology and health. Springer Science & Business Media, New York, 2005.
34. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY and Zhang J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80, 2004.
35. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B and Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: 5, 2003.
36. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003. (Pubitemid 36181903)
37. Bengtsson H, Simpson K, Bullard J and Hansen K: Aroma. Affymetrix: a generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory, in Technical Report #745. Department of Statistics, University of California, Berkeley, 2008.
38. Wilson CL and Miller CJ: Simpleaffy: a BioConductor package for Affymetrix quality control and data analysis. Bioinformatics 21: 3683-3685, 2005. (Pubitemid 41264111)
39. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998. (Pubitemid 28406817)
40. Han ES, Muller FL, Perez VI, et al: The in vivo gene expression signature of oxidative stress. Physiol Genom 34: 112-126, 2008.
41. Jaiswal AK: Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 36: 1199-1207, 2004.
42. Dhakshinamoorthy S, Long DJ and Jaiswal AK: Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr Top Cell Regul 36: 201-206, 2000.
43. Zhang DD: Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 38: 769-789, 2006.
44. Kobayashi M and Yamamoto M: Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 46: 113-140, 2006. (Pubitemid 44301353)
45. Copple IM, Goldring CE, Kitteringham NR and Park BK: The Nrf2-Keap1 defense pathway: role in protection against drug-induced toxicity. Toxicology 246: 24-33, 2008.
46. Jaiswal AK: Regulation of genes encoding NAD(P)H:quinone oxidoreducatases. Free Radic Biol Med 29: 252-254, 2000.
47. Bloom D, Dhakshinamoorthy S, Wang W, Celli CM and Jaiswal AK: Role of NF-E2 related factors in oxidative stress. In: Cell and Molecular Responses to Stress, Protein Adaptation and Signal Transduction. Storey KB and Storey JM (eds). Elsevier, Amsterdam, pp229-238, 2001.
48. Venugopal R and Jaiswal AK: Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 93: 14960-14965, 1996. (Pubitemid 26419078)
49. Alam J, Stewart D, Touchard C, Boinapally S, Choi MK and Cook JL: Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 274: 26071-26078, 1999.
50. Wild AC, Moinova HR and Mulcahy RT: Regulation of g-glutamylcysteine synthetase subunit gene expression by transcription factor Nrf2. J Biol Chem 274: 33627-33636, 1999. (Pubitemid 129511675)
51. Nguygen T, Huang HC and Pickett CB: Transcriptional regulation of the antioxidant gene response element: activation by Nrf2 and repression by MafK. J Biol Chem 275: 15466-15473, 2000. (Pubitemid 30337278)
52. Andrews NC, Erdjument-Bromage H, Davidson MB, Tempst P and Orikin SH: Erythroid transcription factor NF-E2 is a haematopoietic-specific basic leucine zipper protein. Nature 339: 722-727, 1993.
53. Tenhunen R, Marver MS and Schmid R: The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 61: 748-755, 1968.
54. Prawan A, Kundu JK and Surh YJ: Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection. Antioxidants Redox Signaling 7: 1688-1703, 2005. (Pubitemid 41768002)
55. Lu SC: Regulation of glutathione synthesis. Molecular Aspects Medicine 30: 42-59, 2009.
56. Krzywanski DM, Dickinson DA, Iles KE, Wigley AF, Franklin CC, Liu RM, Kavanagh TJ and Forman HJ: Variable regulation of glutamate cysteine ligase subunit proteins affects glutathione biosynthesis in response to oxidative stress. Arch Biochem Biophys 423: 116-125, 2004. (Pubitemid 38198221)
57. Soriano FX, Leveille F, Papadia S, Higgins LG, Varley J, Baxter P, Hayes JD and Hardingham GE: Induction of sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the neuroprotective Nrf2 activator 3H-1,2-dithiole-3-thione. J Neurochem 107: 533-543, 2008.
58. Park JW, Mieyal JJ, Rhee SG and Chock PB: Deglutathionylation of 2-Cys peroxiredoxin is specifically catalyzed by sulfiredoxin. J Biol Chem 284: 23364-23374, 2009.
59. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y and Yodoi J: Identification of thioredoxin-binding protein-2/vitamin D(3) upregulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645-21650, 1999.
60. Patwari P, Higgins LJ, Chutkow WA, Yoshioka J and Lee RT: The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 281: 21884-21891, 2006. (Pubitemid 44181892)
61. Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG and Choi I: Vitamin D3 upregulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164: 6287-6295, 2000. (Pubitemid 30408809)
62. Mitsui A, Hamuro J, Nakamura H, Kondo N, Hirabayashi Y, Ishizaki-Koizumi S, Hirakawa T, Inoue T and Yodoi J: Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal 4: 693-696, 2002. (Pubitemid 35001454)
63. Tonissen KF and Di Trapani G: Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 53: 87-103, 2009.
64. Hong SH, Kim J, Kim JM, Lee SY, Shin DS, Son KH, Han DC, Sung YK and Kwon BM: Apoptosis induction of 2′-hydroxycinnamaldehyde as a proteosome inhibitor is associated with ER stress and mitochondrial perturbation in cancer cells. Biochem Pharmacol 74: 557-565, 2007. (Pubitemid 47042009)
65. Lo M, Ling V, Wang YZ and Gout PW: The Xc-cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer 99: 464-472, 2008.
66. Kim KH, Jeong JY, Surh YJ and Kim KW: Expression of stress-response ATF3 is mediated by Nrf2 in astocytes. Nucleic Acids Res 38: 48-59, 2010.
67. Turchi L, Aberdam I, Mazure N, Pouyssegur J, Deckert M, Kitajima S, Aberdam D and Virolle T: Hif-2alpha mediates UV-induced apoptosis through a novel ATF3-dependent death pathway. Cell Death Differ 15: 1472-1480, 2008.
68. Yoshida T, Sugiura H, Mitobe M, et al: ATF3 protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 19: 217-224, 2008. (Pubitemid 351240643)
69. Lu D, Wolfgang CD and Hai T: Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 281: 10473-10481, 2006. (Pubitemid 43864586)
70. Nakagomi S, Suzuki Y, Namikawa K, Kiryu-Seo S and Kiyama H: Expression of the activating transcription factor 3 prevents c-Jun N-terminal kinase-induced neuronal death by promoting heat shock protein 27 expression and Akt activation. J Neurosci 23: 5187-5196, 2003. (Pubitemid 36793247)
71. Seijffers R, Mills CD and Woolf CJ: ATF3 increases the intrinsic growth rate of DRG neurons to enhance peripheral nerve regeneration. J Neurosci 27: 7911-7920, 2007. (Pubitemid 47173306)
72. Boutros T, Chevet E and Metrakos P: Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 60: 261-310, 2008.
73. Li Y, Bolderson E, Kumar R, Muniandy PA, Xue Y, Richard DJ, Seidman M, Pandita TK, Khanna KK and Wang W: hSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response. J Biol Chem 284: 23525-23531, 2009.
74. Ohtsuka K and Suzuki T: Roles of molecular chaperones in the nervous system. Brain Res Bull 53: 141-146, 2000.
75. Mitra A, Shevde LA and Samant RS: Multi-faceted role of HSP40 in cancer. Clin Exp Metastasis 26: 559-567, 2009.
76. Saulnier Sholler GL, Bergendahl GM, Brard L, Singh AP, Heath BW, Bingham PM, Ashikaga T, Kamen BA, Homans AC, Slavik MA, Lenox SR, Higgins TJ and Ferguson WS: A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. J Pediatr Hematol Oncol 33: 25-30, 2011.